Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will determine the maximum tolerated dose of the triplet combination of
capecitabine that can be administered in combination with weekly paclitaxel and every four
weeks with carboplatin.